Mark Rolfe
Impact in
- Oncology top 1%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cell Biology top 1%
- Microtubule and mitosis dynamics
Papers in
-
- Ubiquitin and proteasome pathways 25
- Protein Degradation and Inhibitors 11
- Oncology 25
- Cancer-related Molecular Pathways 8
- HER2/EGFR in Cancer Research 5
- Co-authors
- Peggy Beer‐Romero (4 shared papers)Michele Pagano (3 shared papers)Anne M. Theodoras (3 shared papers)Giulio Draetta (2 shared papers)Giannino Del Sal (1 shared paper)Vincent Chau (1 shared paper)P. Renée Yew (1 shared paper)Sun W. Tam (1 shared paper)
- Journals
- Blood (6 papers)Cancer Research (5 papers)Molecular Cancer Therapeutics (4 papers)American Journal of Clinical Pathology (4 papers)Clinical Cancer Research (3 papers)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Mark Rolfe
53 papers receiving 5.9k citations
Mark Rolfe's Hit Papers
Peers
Comparison fields: 5 of 124
- Oncology 2.5k
- Cell Biology 1.2k
- Molecular Biology 4.6k
- Hematology 471
- Cancer Research 570
Countries citing papers authored by Mark Rolfe
This map shows the geographic impact of Mark Rolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rolfe more than expected).
Fields of papers citing papers by Mark Rolfe
This network shows the impact of papers produced by Mark Rolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rolfe. The network helps show where Mark Rolfe may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Rolfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 55 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27 Hit paper breakdown → | 1995 | 1629 |
| 2 | A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B Hit paper breakdown → | 1995 | 826 |
| 3 | Drug discovery in the ubiquitin–proteasome system Hit paper breakdown → | 2006 | 503 |
| 4 | 2010 | 409 | |
| 5 | 2010 | 270 | |
| 6 | 2004 | 211 | |
| 7 | 2010 | 188 | |
| 8 | 2009 | 184 | |
| 9 | 2015 | 146 | |
| 10 | 2006 | 141 | |
| 11 | 2003 | 125 | |
| 12 | 1997 | 91 | |
| 13 | 2006 | 88 | |
| 14 | 1997 | 88 | |
| 15 | 2002 | 86 | |
| 16 | 1995 | 83 | |
| 17 | 2001 | 65 | |
| 18 | 2020 | 65 | |
| 19 | 2003 | 63 | |
| 20 | 2019 | 63 |
About Mark Rolfe
Mark Rolfe is a scholar working on Molecular Biology, Oncology, Genetics, Cell Biology and Cancer Research, having authored 55 papers that have together received 6.0k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (25 papers), Protein Degradation and Inhibitors (11 papers), Cancer-related Molecular Pathways (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), NF-κB Signaling Pathways (6 papers), Endoplasmic Reticulum Stress and Disease (5 papers), HER2/EGFR in Cancer Research (5 papers) and Multiple Myeloma Research and Treatments (5 papers). The work is most often cited by research in Oncology (2.5k citations), Cell Biology (1.2k citations), Molecular Biology (4.6k citations), Hematology (471 citations) and Cancer Research (570 citations). Mark Rolfe has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Peggy Beer‐Romero, Michele Pagano, Anne M. Theodoras, Giulio Draetta, Giannino Del Sal, Vincent Chau, P. Renée Yew, Sun W. Tam, Grzegorz Nalepa and J. Wade Harper. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, American Journal of Clinical Pathology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.